Outlook Wealth Advisors LLC bought a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 3,347 shares of the medical research company's stock, valued at approximately $590,000.
Several other hedge funds and other institutional investors have also recently modified their holdings of the company. American National Bank & Trust bought a new position in IQVIA in the first quarter worth approximately $26,000. ST Germain D J Co. Inc. increased its stake in shares of IQVIA by 66.1% in the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock worth $34,000 after purchasing an additional 76 shares in the last quarter. GKV Capital Management Co. Inc. bought a new position in IQVIA in the 4th quarter worth $39,000. Lee Danner & Bass Inc. bought a new position in IQVIA in the 4th quarter worth $44,000. Finally, Zions Bancorporation N.A. lifted its position in IQVIA by 55.2% during the fourth quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock valued at $47,000 after purchasing an additional 85 shares in the last quarter. 89.62% of the stock is owned by institutional investors.
Analyst Ratings Changes
Several research analysts have recently commented on the company. Wall Street Zen downgraded IQVIA from a "buy" rating to a "hold" rating in a research note on Wednesday, March 12th. Redburn Partners set a $188.00 target price on shares of IQVIA in a report on Friday, May 23rd. JPMorgan Chase & Co. decreased their target price on shares of IQVIA from $232.00 to $177.00 and set an "overweight" rating on the stock in a research note on Monday, May 19th. Mizuho dropped their price target on shares of IQVIA from $210.00 to $190.00 and set an "outperform" rating for the company in a research report on Thursday, May 15th. Finally, HSBC cut shares of IQVIA from a "buy" rating to a "hold" rating and reduced their price objective for the stock from $260.00 to $160.00 in a research note on Friday, April 25th. Eight equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $226.32.
Get Our Latest Report on IQV
IQVIA Price Performance
Shares of IQV stock traded up $0.05 on Thursday, reaching $158.88. The company's stock had a trading volume of 1,584,470 shares, compared to its average volume of 1,612,288. The stock's fifty day simple moving average is $147.21 and its 200-day simple moving average is $178.30. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $252.88. The company has a market capitalization of $27.49 billion, a price-to-earnings ratio of 21.18, a price-to-earnings-growth ratio of 1.99 and a beta of 1.28. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12.
IQVIA (NYSE:IQV - Get Free Report) last posted its earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, topping analysts' consensus estimates of $2.63 by $0.07. IQVIA had a net margin of 8.91% and a return on equity of 28.81%. The firm had revenue of $3.83 billion for the quarter, compared to the consensus estimate of $3.77 billion. During the same period in the previous year, the firm posted $2.54 EPS. The business's quarterly revenue was up 2.5% on a year-over-year basis. Analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.
IQVIA Company Profile
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Read More
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
